Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, reversibly binding P2Y12 receptor antagonist. It is used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** For the prevention of thrombotic events in patients with a history of myocardial infarction (MI). Typically used in conjunction with aspirin.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or as recommended by guidelines. In some cases, the dose may be reduced to 60 mg twice daily after the initial 12-month period for patients who have completed a course of treatment for ACS and are at high risk for ischemic events but low risk for bleeding.
## Pediatric Dosing
* **Ticagrelor is not recommended for use in pediatric patients.** Dosing has not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is necessary in patients with mild, moderate, or severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment due to lack of data.
## Contraindications
* Known hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding.
## Adverse Effects
* **Major Bleeding:** Including intracranial and fatal bleeding.
* **Dyspnea:** Most commonly reported side effect, usually mild and transient.
* **Bradycardia:** May occur, especially in patients taking other medications that cause bradycardia.
* **Ventricular pauses, AV block.**
* **Increased creatinine.**
* **Hyperuricemia.**
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 substrates (e.g., simvastatin, atorvastatin, certain calcium channel blockers) may increase exposure to these drugs. Consider alternative statin doses or agents.
* **CYP3A4 Inhibitors/Inducers:** Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin). Use with caution with strong CYP3A4 inducers (e.g., rifampin).
* **Aspirin:** Concomitant use with aspirin is generally recommended for ACS patients, but increases bleeding risk. Optimal duration of dual antiplatelet therapy (DAPT) should be individualized.
* **Anticoagulants:** Concomitant use increases the risk of bleeding.
## Monitoring
* **Signs and symptoms of bleeding:** Monitor for any evidence of bleeding (e.g., hematuria, epistaxis, GI bleeding, bruising).
* **Renal function:** Monitor serum creatinine, especially in patients with renal impairment or those taking other nephrotoxic agents.
* **Ventricular rate:** Monitor ECG for bradycardia or AV block.
## Clinical Pearls
* Ticagrelor is dosed **twice daily**, unlike clopidogrel (once daily) and prasugrel (once daily).
* Unlike clopidogrel and prasugrel, ticagrelor does not require a loading dose of aspirin, although it is often given together. Aspirin dose should be kept as low as clinically indicated.
* Discontinuation of ticagrelor prematurely increases the risk of stent thrombosis, MI, and death.
* Patients experiencing dyspnea should not necessarily have ticagrelor discontinued; reassess the cause.
***
**Disclaimer:** This information is intended for clinical decision support and does not replace professional judgment. Always consult the current official prescribing information for the most up-to-date and complete details regarding indications, contraindications, warnings, precautions, adverse reactions, drug interactions, and dosing.
